Valeant selects trio to fill in for ailing CEO; shares dive
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Valeant Pharmaceuticals (VRX) Bounces Day After Sharp Drop on CEO Medical Leave
December 29, 2015 9:13 AM ESTAfter dropping 10.5% Monday on news the CEO has been hospitalized with severe pneumonia and has taken an medical leave, Valeant Pharmaceuticals (NYSE: VRX) is up 1.3% this morning as investors bet on a positive outcome and see yesterday's selling as an overreaction.
... More